Previous close | 19.40 |
Open | 19.40 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 120.00 |
Expiry date | 2026-01-16 |
Day's range | 19.40 - 19.40 |
Contract range | N/A |
Volume | |
Open interest | 597 |
RAHWAY, N.J., May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. The FDA has set a Prescription Drug User Fee
RAHWAY, N.J. & NEW YORK, May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
** Anglo American rejected BHP Group's last-ditch request for more time to discuss a $49 billion takeover offer, dismissing it as highly complex and ending a five-week pursuit by the bigger rival. ** A consortium of U.S. investment firm KKR and Singapore Telecommunications (SingTel) has emerged as the frontrunner to buy a minority stake worth $1 billion in one of Asia's biggest data centre providers, two sources said. ** The owner of Britain's Royal Mail has agreed to a 3.57 billion pound ($4.55 billion) takeover by Czech billionaire Daniel Kretinsky, it said on Wednesday, in a take-private deal of one of the world's oldest postal firms.